Live
- GAIL clocks net profit of Rs 2,672 crore in Q2
- Sr Men's National Hockey: Delhi, Karnataka, Bengal, A.P. win group matches on Day 2
- ‘Nation is proud of you’: West Bengal Guv to GRSE on laying keels of two NGOPVS
- Kirttane, Kapadia bag golden double as India wins 14 medals in Asia Pickleball Games
- Gurugram: 11 projects of GMDA worth Rs 249.77 crores approved
- Akali Dal stages statewide protests over ‘tardy’ paddy procurement in Punjab
- Firing on Nandan Kanan Express in Odisha, probe launched
- Indian Army Seizes Massive Cache Of Arms And Ammunition In Manipur Amid Ongoing Violence
- Polling Stations Open Across Eastern And Central US As Voters Head To The Ballots In Historic Election
- Hyatt set to expand brand presence in Nepal with hyatt regency lumbini
Coronavirus: AstraZeneca vaccine trial volunteer dies in Brazil, testing to continue
AstraZeneca COVID-19 vaccine trial volunteer dies in Brazil
Anvisa, Brazilian health authority confirmed that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca NSE -1.93 %.
On Wednesday, Anvisa, Brazilian health authority confirmed that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca NSE -1.93 % and Oxford University had died, but the trial would continue.
Oxford confirmed the plan to continue trials, saying in a statement that after careful assessment "there have been no concerns about the safety of the clinical trial." Brazilian newspaper O Globo reported that the volunteer had been given a placebo and not the trial vaccine, citing unnamed sources.
Anvisa provided no further details, citing medical confidentiality of those involved in trials.
AstraZeneca didn't comment immediately. The Federal University of Sao Paulo is helping coordinate phase 3 clinical trials in Brazil, individually said the volunteer was Brazilian without disclosing where the person lived.
AstraZeneca shares came down by 1.7%.
The federal government is planning to purchase the UK vaccine and produce it at its biomedical research centre FioCruz in Rio de Janeiro. In contrast, a competing vaccine from China's Sinovac Biotech Ltd is being tested by Sao Paulo state's research centre Butantan Institute.
Brazil has more than 154,000 killed by COVID-19, it has the second deadliest outbreak of coronavirus, after the United States. It has more than 5.2 million infected, the third-largest number of cases, after the United States.
